5 results match your criteria: "ADI International Institute for Advancement of Drug Development[Affiliation]"
Mature brain-derived neurotrophic factor (BDNF) is the major player of total BDNF in serum regarding prediction of antidepressant treatment outcome.
Psychopharmacology (Berl)
January 2016
Neurobiology Laboratory for Brain Aging and Mental Health, Transfaculty Research Platform Molecular and Cognitive Neuroscience, University of Basel and Psychiatric Clinics of the University of Basel, Basel, Switzerland.
Among a variety of drugs used in the treatment of anxiety disorders, benzodiazepines and antidepressants such as selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) are at present the most established and prescribed. In fact, recent guidelines recommend the antidepressants SSRI and SNRI as well as pregabaline, a newly developed drug, as the 1st choice treatment in generalized anxiety disorder (GAD). However, antidepressants have several disadvantages (latency of onset of action, adverse effects and drug interactions) that should not be neglected.
View Article and Find Full Text PDFArticle Synopsis
- Anxiety disorders are long-lasting conditions that cause significant distress, and benzodiazepines are the most effective medication with potential issues like dependence.
- The use of benzodiazepines should be limited to the initial treatment phase alongside SSRIs or SNRIs, with a tapering process after a few weeks as antidepressants begin to work.
- First-line antidepressants can have common side effects that some patients find intolerable, and combining therapies may enhance treatment results, but overall, more research is needed to improve remission rates, which are currently only about 40%.
The results of the Swiss observational study of the new, fast-dissolving mirtazapine formulation in depressed patients.
Int J Psychiatry Clin Pract
June 2014
ADI International Institute for Advancement of Drug Development, Basel, Switzerland.
Objective. The purpose of the present study was to document the experience with the use of a new, fast-dissolving oral tablet (FDT, RemeronSolTab®) of mirtazapine, a NaSSA antidepressant, in the treatment of depressed patients in daily practice in Switzerland. Methods.
View Article and Find Full Text PDF[Drug therapy in sleep disorders].
Rev Med Suisse Romande
May 2001
ADI International Institute for Advancement of Drug Development, Mittlerestrasse 2, 4056 Bâle.